The majority of physicians agree there is a need for effective risk stratification to enable early, accurate and cost-effective identification of those individuals who would benefit from therapeutic interventions. However, there is a lack of consensus on the use and utility of novel assessment tools that may identify at-risk patients and provide valuable surrogate endpoints. Please share with us your thoughts on the use of biomarkers in clinical care.
Join Drs Linde, Daubert and Gold in an intriguing discussion on the impact of cardiac resynchronization therapy on remodeling and disease progression, with a review of new data by Dr Abraham.
Are you hip to SNPs? Dr Eric Topol discusses the identification of genetic variants associated with an increased risk for cardiovascular disease and their potential application to patient management. You can also download Dr Christopher Granger's PowerPoint overview of genetics for the cardiologist.
Drs Weber and Nissen run down and give perspective to heartwire stories on the topic of prevention that were the most important in 2007. Which stories give evidence of progress and which stories have proven controversial? Enjoy their fast moving commentary.
From the bench to the bedside: Old and new markers of target organ disease advance the understanding of chronic kidney disease, but what are the strategies that are now being tested in the clinic? Drs Ibrahim, Gansevoort and Tobe discuss advances in chronic kidney disease and how it translates to reducing cardiovascular outcomes.
Life saving drugs: Is one RAAS blocker better than others? Are two better than either one? How can we make the right choice for the patient? Do we have the data to support clinical decisions?
Many uncertainties still abound about optimal management of patients at high risk for CV events. The ONTARGET trial is the most ambitious attempt to find the right answers.
This new resource center is conceived to provide key articles, slide kits and support material to physicians and healthcare providers involved in the care of patients presenting with any of the cardiovascular risks. This is a site that offers information and data you may not easily find elsewhere! Take advantage of this tool and learn more about cardiovascular risks.
Hear what the experts have to say about ESH 2007: Join Dr Weber as he discusses topics ranging from microalbuminuria, cardiovascular risk and the new ESH/ESC Hypertension Guidelines with Drs Mancia, Hermida, Meredith, Schmeider, Collier and Lacy.
Angiotensin receptor blockers (ARBs) not only provide blood pressure control but also have important blood pressure-independent benefits. Please join Drs Mancia, Burgess and McInnes as they discuss how ARBs may help to address total cardiovascular risk across the cardiovascular continuum.
Clinicians now have 3 alternatives to block the complex Renin-Angiotensin-System, as well as the option of combining agents. Does it really matter which option is used? A panel discussion examines this question with Drs Weber, Dzau, Gorelick, and Hollenberg.
There has been much discussion regarding the importance of heart rate (HR) as a prognostic index of cardiovascular risk. Recent data strongly suggest that the beneficial effects of drug treatment, in areas such areas as postmyocardial infarction prophylaxis and heart failure, may be due to its ability to reduce HR. The exact mechanism(s) by which a HR under control confers its protection to the myocardium has yet to be elucidated, but may be related to hemodynamic stabilization that may reduce the pathogenesis of plaque disruption and also be anti-ischaemic, antiarrhythmic and anti-atherosclerotic.
The AMADEO trial: The very first head-to-head comparison of ARBs for differences in proteinuria or kidney disease progression. See how reducing blood pressure in hypertensive diabetics can benefit the kidneys.
As the population ages and the prevalence of hypertension increases worldwide, clinicians need to recognize that poorly controlled hypertension leads to the development of cardiovascular disease. Clinicians must remain up-to-date with best practices in the management of hypertension as ways to improve patient awareness, compliance and prevention of comorbidities.
Chronic kidney disease and cardiovascular disease: Double trouble leads to more morbidity and mortality. What new therapies offer promise for patients with chronic kidney disease?
Cardiovascular (CV) disease is the single leading cause of death in the United States. Multiple risk factors such as hypertension, diabetes, obesity, and dyslipidemia contribute to multiple pathophysiologic/neurohormonal processes that affect the development of CV disease. This program will review current and emerging approaches to CV risk management. CME Provider: The Academy for Healthcare Education, Inc. Supported by an educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.
Drs Weber and Nissen run down and give perspective to heartwire stories on the topic of prevention that were the most important in 2007. Which stories give evidence of progress and which stories have proven controversial? Enjoy their fast moving commentary.
Are you hip to SNPs? Dr Eric Topol discusses the identification of genetic variants associated with an increased risk for cardiovascular disease and their potential application to patient management. You can also download Dr Christopher Granger's PowerPoint overview of genetics for the cardiologist.
The majority of physicians agree there is a need for effective risk stratification to enable early, accurate and cost-effective identification of those individuals who would benefit from therapeutic interventions. However, there is a lack of consensus on the use and utility of novel assessment tools that may identify at-risk patients and provide valuable surrogate endpoints. Please share with us your thoughts on the use of biomarkers in clinical care.
Join Drs Linde, Daubert and Gold in an intriguing discussion on the impact of cardiac resynchronization therapy on remodeling and disease progression, with a review of new data by Dr Abraham.